Background: We recently demonstrated in a randomized controlled trial (APOMORPHEE, NCT02940912) that night-time only subcutaneous apomorphine infusion improves sleep disturbances and insomnia in patients with advanced Parkinson's disease and moderate to severe insomnia.
Objectives: To identify the best candidates for receiving night-time only subcutaneous apomorphine infusion in routine care.
Methods: In this post-hoc analysis of APOMORPHEE, we compared the characteristics of patients according to whether they chose to continue night-time only subcutaneous apomorphine infusion at the end of the study period or not.
Results: Half of the patients (22/42) chose to continue the treatment. Off duration (day or night), painful Off dystonia, and insomnia severity at baseline were associated with night-time only apomorphine continuation. Multivariate analysis retained only Off duration as an independent predictor of continuation.
Conclusions: The best candidates for night-time only apomorphine are patients with severe and prolonged Off periods (day or night) and severe insomnia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450238 | PMC |
| http://dx.doi.org/10.1002/mdc3.13799 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- * Data was collected from 37 patients treated between 2011 and 2022, highlighting that half started nocturnal treatment for motor issues, while others suffered from various non-motor symptoms.
- * The findings show 54% of patients maintained treatment by the end, with some discontinuing due to adverse reactions, indicating the treatment's overall effectiveness and safety despite some challenges.
Gender disparity in access to advanced therapies for patients with Parkinson's disease: a retrospective real-word study.
Front Neurol
September 2024
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Background: Gender differences in the access to advanced therapies for Parkinson's disease (PD) are poorly investigated.
Objective: The objective of this study was to investigate the presence of any gender disparity in the access to advanced therapies for PD.
Design: Retrospective study.
Vestibular Neurostimulation for Parkinson's Disease: A Novel Device-Aided Non-Invasive Therapeutic Option.
J Pers Med
August 2024
Scion NeuroStim, Inc., Durham, NC 27707, USA.
Dopaminergic replacement therapy remains the mainstay of symptomatic treatment for Parkinson's disease (PD), but many unmet needs and gaps remain. Device-based treatments or device-aided non-oral therapies are typically used in the advanced stages of PD, ranging from stereotactic deep brain stimulation to levodopa or apomorphine infusion therapies. But there are concerns associated with these late-stage therapies due to a number of procedural, hardware, or long-term treatment-related side effects of these treatments, and their limited nonmotor benefit in PD.
View Article and Find Full Text PDFApomorphine Subcutaneous Infusion Likely Induced Acute Thrombocytopenia in a Patient with Parkinson's Disease and Motor Fluctuations.
Mov Disord Clin Pract
September 2024
Parkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, Pavia, Italy.
Influence of continuous subcutaneous apomorphine infusion on cognition and behavior in Parkinson's disease: A systematic review.
Rev Neurol (Paris)
August 2024
Neurology and Movement Disorders Department, NS-Park/F-CRIN, Lille Neurosciences and Cognition, CHU de Lille, University Lille, Inserm, 59000 Lille, France.
Introduction: The efficacy of continuous subcutaneous apomorphine infusion (CSAI) for motor complications of Parkinson's disease (PD) is established. However, its effect on cognition and behavior remains controversial. The main objective of this systematic review was to describe the existing literature on the effects of CSAI on cognition and behavior and to determine the quality for each study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!